Exact Sciences : EEO-1 for the FY ended 12/19/2021
June 29, 2024 at 01:22 am IST
Share
Exact Sciences is committed to disclosing meaningful information regarding our efforts to create a diverse, equitable, and inclusive workplace. To us, diversity means our team reflects a variety of unique identities, cultures, thoughts and lived experiences. With this commitment, we are disclosing our EEO-1 survey data, representing U.S. employees as of December 2023. We note that our EEO-1 survey data present demographic information in federally mandated job categories that don't fully speak to the diversity of our workplace and how we embed diversity, equity, and inclusion into the company . We are firmly committed to providing equal opportunity in all aspects of employment and will not discriminate in any employment decision because of a person's race, color, sex, religion, national origin, age, disability, sexual orientation, gender identity, genetic information, veteran status, or any other basis prohibited by applicable law.
CO= FN48101
U= FN48101
SECTION B - COMPANY IDENTIFICATION
1. EXACT SCIENCES CORPORATION 5505 ENDEAVOR LANE MADISON, WI 53719
EQUAL EMPLOYMENT OPPORTUNITY 2021 EMPLOYER INFORMATION REPORT EEO-1
DATES OF PAYROLL PERIOD: 12/12/2021 THRU 12/25/2021
SECTION G - CERTIFICATION
CERTIFIED DATE [EST]: 5/12/2022 9:15:00 AM
CERTIFYING OFFICIAL: ANTHONY VENKI
TITLE: Compensation Analyst
EMAIL: tschiffman@exactsciences.com
PHONE: 844-870-8870
EEO1 REPORT CONTACT PERSON: ANTHONY VENKI
TITLE: Compensation Analyst
EMAIL: tschiffman@exactsciences.com
PHONE: 844-870-8870
Attachments
Original Link
Original Document
Permalink
Disclaimer
EXACT Sciences Corporation published this content on
28 June 2024 and is solely responsible for the information contained therein. Distributed by
Public, unedited and unaltered, on
28 June 2024 19:51:08 UTC.
Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening, MCED Test Development and MRD Test Development. The Companyâs products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, and OncoExTra Test. The Companyâs flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patientâs breast tumor tissue.